The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer
Abstract Non-small cell lung cancer (NSCLC) remains a dire disease being the first cause of cancer death among both genders. Early-stage NSCLC often has better treatment outcomes despite it being a highly heterogeneous disease. So far, the neo-adjuvant chemotherapy strategies have led to a small ben...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-01826-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571564205277184 |
|---|---|
| author | Gaia Passarella Stefania Canova Maria Ida Abbate Giulia Caspani Luca Sala Alessandro Russo Paola Muscolino Francesca Colonese Diego Luigi Cortinovis |
| author_facet | Gaia Passarella Stefania Canova Maria Ida Abbate Giulia Caspani Luca Sala Alessandro Russo Paola Muscolino Francesca Colonese Diego Luigi Cortinovis |
| author_sort | Gaia Passarella |
| collection | DOAJ |
| description | Abstract Non-small cell lung cancer (NSCLC) remains a dire disease being the first cause of cancer death among both genders. Early-stage NSCLC often has better treatment outcomes despite it being a highly heterogeneous disease. So far, the neo-adjuvant chemotherapy strategies have led to a small benefit with an improvement of 5% in overall survival as an absolute benefit. Recently, the introduction of immune checkpoint inhibitors combined with chemotherapy has shown robust efficacy in terms of event-free survival and overall survival. Thus, these combinations are today considered a new standard of care in early-stage NSCLC. The application of these strategies to all-comer population lead to confounding definitive results regarding the efficacy and predictive biomarkers are urgently needed balancing the promise of healing than toxicities. At present, the clinical staging TNM system guides the clinical choice, however it is not entirely sufficient. Circulant tumoral DNA (ctDNA) emerged as a promising prognostic and predictive biomarker that may guide the future perioperative strategy and pave the way to personalized medicine also in this exciting field. This narrative review aims to put in the context the employment of ctDNA, give some perspective and suggestions weighing the pros and cons of this technique for our tomorrow clinical practice. |
| format | Article |
| id | doaj-art-14d7dbfbb73e41749718250deeb45c0f |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-14d7dbfbb73e41749718250deeb45c0f2025-02-02T12:30:31ZengSpringerDiscover Oncology2730-60112025-01-0116111510.1007/s12672-025-01826-7The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancerGaia Passarella0Stefania Canova1Maria Ida Abbate2Giulia Caspani3Luca Sala4Alessandro Russo5Paola Muscolino6Francesca Colonese7Diego Luigi Cortinovis8Medical Oncology Unit, Fondazione IRCCS San Gerardo dei TintoriMedical Oncology Unit, Fondazione IRCCS San Gerardo dei TintoriMedical Oncology Unit, Fondazione IRCCS San Gerardo dei TintoriMedical Oncology Unit, Fondazione IRCCS San Gerardo dei TintoriMedical Oncology Unit, Fondazione IRCCS San Gerardo dei TintoriDepartment of Medical Oncology, Humanitas Istituto Clinico CataneseDepartment of Human Pathology “G. Barresi”, Medical Oncology Specialization School, University of MessinaMedical Oncology Unit, Fondazione IRCCS San Gerardo dei TintoriMedical Oncology Unit, Fondazione IRCCS San Gerardo dei TintoriAbstract Non-small cell lung cancer (NSCLC) remains a dire disease being the first cause of cancer death among both genders. Early-stage NSCLC often has better treatment outcomes despite it being a highly heterogeneous disease. So far, the neo-adjuvant chemotherapy strategies have led to a small benefit with an improvement of 5% in overall survival as an absolute benefit. Recently, the introduction of immune checkpoint inhibitors combined with chemotherapy has shown robust efficacy in terms of event-free survival and overall survival. Thus, these combinations are today considered a new standard of care in early-stage NSCLC. The application of these strategies to all-comer population lead to confounding definitive results regarding the efficacy and predictive biomarkers are urgently needed balancing the promise of healing than toxicities. At present, the clinical staging TNM system guides the clinical choice, however it is not entirely sufficient. Circulant tumoral DNA (ctDNA) emerged as a promising prognostic and predictive biomarker that may guide the future perioperative strategy and pave the way to personalized medicine also in this exciting field. This narrative review aims to put in the context the employment of ctDNA, give some perspective and suggestions weighing the pros and cons of this technique for our tomorrow clinical practice.https://doi.org/10.1007/s12672-025-01826-7Non-small cell lung cancerEarly stageNeoadjuvant therapyAdjuvant therapyPerioperative therapyLiquid biopsy |
| spellingShingle | Gaia Passarella Stefania Canova Maria Ida Abbate Giulia Caspani Luca Sala Alessandro Russo Paola Muscolino Francesca Colonese Diego Luigi Cortinovis The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer Discover Oncology Non-small cell lung cancer Early stage Neoadjuvant therapy Adjuvant therapy Perioperative therapy Liquid biopsy |
| title | The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer |
| title_full | The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer |
| title_fullStr | The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer |
| title_full_unstemmed | The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer |
| title_short | The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer |
| title_sort | hype around ctdna guiding an informed perioperative therapeutic strategy in early stage non small cell lung cancer |
| topic | Non-small cell lung cancer Early stage Neoadjuvant therapy Adjuvant therapy Perioperative therapy Liquid biopsy |
| url | https://doi.org/10.1007/s12672-025-01826-7 |
| work_keys_str_mv | AT gaiapassarella thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT stefaniacanova thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT mariaidaabbate thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT giuliacaspani thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT lucasala thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT alessandrorusso thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT paolamuscolino thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT francescacolonese thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT diegoluigicortinovis thehypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT gaiapassarella hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT stefaniacanova hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT mariaidaabbate hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT giuliacaspani hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT lucasala hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT alessandrorusso hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT paolamuscolino hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT francescacolonese hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer AT diegoluigicortinovis hypearoundctdnaguidinganinformedperioperativetherapeuticstrategyinearlystagenonsmallcelllungcancer |